Comparison of Definitive Radiotherapy in the Young-Elderly and Elderly with Clinical Localized Prostate Cancer
- 1 November 2021
- journal article
- research article
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 22 (4), 326-331
- https://doi.org/10.4274/imj.galenos.2021.29000
Abstract
Introduction: This study aimed to investigate the survival, treatment-related toxicitics, and prognostic factors in the elderly (>= 65) with prostate cancer treated with definitive radiotherapy (RT). Patients divided into two groups as youngold (65-74 years) and old (over 75 years) were examined. Methods: A total of 178 patients with prostate cancer treated with definitive RT were retrospectively reviewed. The prognostic factors for survival, metastasis-free survival (MFS), biochemical recurrence-free survival (BFS), and treatment-related toxicities were analyzed. Results: Pretreatment prostate-specific antigen (PSA), last PSA value, and Charlson comorbidity score (5-6) were significantly different between the two groups (p=0.001, p=0.004, and p=0.012, respectively). The elderly showed high pretreatment PSA, last PSA value, and Charlson comorbidity score (5-6). None of the other treatment or patient characteristics differed significantly between the groups. The median follow-up time was 68 months (range: 12-116 months) for the young-elderly. The 5-year overall survival (OS), BFS, and MFS were 86.4%, 91.5%, and 92.8%, respectively, in the young-elderly. Median follow-up time in the elderly patients was 60 months (range: 7-118 months) and 5-year OS, MFS, and BFS rates were 79.6%, 93.1%, and 93.4%, respectively. No statistical difference was found when the OS, BFS, and MFS were evaluated in 5 years in both groups. The multivariate analysis revealed that high radiation doses (76 Gy and >= 78 Gy) and high T-stage (T3-4) was a significant prognostic factor for the BFS in all patients (p=0.013, p=0.007, and p=0.026, respectively). The presence of high-risk patients in the risk stratification was borderline significant for the BFS (p=0.051). Acute hematological toxicity, such as leucopenia (38%), and late toxicity, such as rectal bleeding (10%), were frequently observed in the elderly. Conclusion: No differences were found in the OS, BFS, and M FS between the two groups. High radiation doses and high T-stage was found as a prognostic factor for the BFS in all patients.This publication has 12 references indexed in Scilit:
- Outcomes of patients older than 75 years with non-metastatic prostate cancerAsian Journal of Urology, 2017
- Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate CancerJournal of Clinical Oncology, 2015
- Dose Escalation for Prostate Cancer Radiotherapy: Predictors of Long-Term Biochemical Tumor Control and Distant Metastases–Free Survival OutcomesEuropean Urology, 2011
- 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized TrialInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Impact of Age at Diagnosis on Prostate Cancer Treatment and SurvivalJournal of Clinical Oncology, 2011
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing NationJournal of Clinical Oncology, 2009
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortalityJournal of Clinical Epidemiology, 2004